American biopharmaceutical company Gilead Sciences on Monday said its antiviral drug offered a modest benefit to patients with moderate COVID-19 symptoms.
The drug forms part of the World Health Organisation’s (WHO) solidarity trial, an international clinical trial to help find an effective treatment for the virus.
Over 375,000 people have died globally from the coronavirus, and more than 6.2 million have been infected.
In the absence of a COVID-19 vaccine, the therapeutics to effectively treat the disease are being closely monitored around the world.
Gilead Sciences said the Ebola drug, Remdesivir, was the first to show improvement in COVID-19 patients in formal clinical trials.
Remdesivir was being closely watched after the US Food and Drug Administration granted emergency use authorisation last month.
Meanwhile, Japan reported 37 new coronavirus cases and two COVID-19 deaths on Monday.
Tokyo moved into its recovery plan this week, which eased restrictions on shopping malls and sports facilities.
China reported five new imported coronavirus cases, but no additional deaths.
Nearly 26,000 nursing home residents died from COVID-19 in the US. Officials said this occurred mostly in poorly rated facilities with weaker infection control.
More Stories
Africa Must Ramp Up Food Production
World Bids Final Farewell To Queen Elizabeth
Biden’s Taiwan Remarks ‘Severely Violate’ US Policy Over Island Says China
COVID-19 6th Wave Delay Indicates Possible End of Pandemic Says Experts
Africa Has An Untapped Export Potential Of $31 Billion
End Of The COVID-19 Pandemic ‘Is In Sight’ – WHO
Boeing Forecasts Demand for 1,010 New Airplanes In Africa
Ukraine Says It Pushed Back Russian Forces And Reclaimed Some Territory
Mixed Feelings Among Some In Africa For Queen Elizabeth
King Charles Vows To Serve His Nation As Britain Mourns Late Queen
After A Lifetime Of Preparation, Charles Takes The Throne
Queen Elizabeth II Dies At 96